SCHEDULE: FMR LLC Discloses 5.1% Stake in Trevi Therapeutics

FMR LLC and Abigail P. Johnson have reported a 5.1% beneficial ownership stake in Trevi Therapeutics Inc. common stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, beneficially own 6,500,009.33 shares of Trevi Therapeutics Inc. common stock.
• This ownership represents 5.1% of the outstanding common stock of Trevi Therapeutics Inc.
• FMR LLC holds sole voting power over 6,485,775.00 shares and sole dispositive power over 6,500,009.33 shares.
• Abigail P. Johnson, as an individual, holds sole dispositive power over 6,500,009.33 shares, with no sole or shared voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institutional investor like FMR LLC can be interpreted as a vote of confidence in Trevi Therapeutics Inc.'s long-term potential, even if it's a passive investment.

Positives

• A significant institutional investor, FMR LLC (Fidelity), has taken a 5.1% stake in Trevi Therapeutics Inc., indicating potential confidence in the company's long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist position aimed at influencing control.

Risks

• No specific risks related to Trevi Therapeutics Inc. are detailed in this beneficial ownership filing; the filing primarily concerns the ownership structure of FMR LLC and its affiliates.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Trevi Therapeutics Inc.'s future outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a major institutional investor like FMR LLC (Fidelity) in a biotechnology company such as Trevi Therapeutics Inc. can signal increased institutional confidence in the company's pipeline or market position. This type of investment often attracts attention from other institutional and retail investors, potentially influencing market perception and liquidity, especially in the often volatile biotech sector.

Comparison to Industry Standards

• FMR LLC, through its various investment advisory subsidiaries like Fidelity Management & Research Company LLC, is a prominent global asset manager. Their investment in Trevi Therapeutics Inc. aligns with typical institutional strategies of building diversified portfolios, often including emerging biotechnology companies.
• While specific comparable companies or projects are not mentioned in the filing, a 5.1% stake is a standard threshold for beneficial ownership reporting, indicating a significant but non-controlling passive investment.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract more institutional interest, which could positively impact share price stability and liquidity.
• Company Management: A large institutional holder like FMR LLC, while passive, represents a significant shareholder base that management will need to consider in its strategic decisions.

Key Dates

Recommendation

The filing indicates a significant institutional investment by FMR LLC, suggesting a positive long-term view from a major player. However, as a Schedule 13G, it provides no operational or financial updates on Trevi Therapeutics Inc. itself. Without further information on the company's performance, pipeline, or strategic direction, a 'hold' recommendation is prudent for existing investors, while potential new investors should conduct further due diligence beyond this ownership disclosure.

Keywords

Trevi Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Fidelity, Biotechnology, Pharmaceuticals